Furthermore, the operating surgeons confirmed that the product is simple to use and apply. These results confirm that our new adhesion prevention technology is sound and surgeons with a highly effective solution to minimize patient discomfort and complications. A significant number of patients with adhesions develop complications which range from discomfort, chronic pain and infertility , to life-threatening problems such as for example small bowel obstruction. Post-medical adhesions continue to be a significant concern, following intra-abdominal and pelvic surgery especially, and are considered the most frequent complication in abdominopelvic surgery now.. Actamax reports positive results from first clinical study of novel sprayable adhesion barrier device Actamax, JV between DuPont and DSM, Releases Positive Findings Actamax Surgical Components LLC, a DSM-DuPont Joint Venture focusing on the development and commercialization of resorbable, biocompatible surgical medical products, today announced positive efficacy and safety outcomes from the first clinical evaluation of it is novel adhesion barrier gadget.An interview with Professor Lesley JonesMartin’s comments came in response to actions used by the FDA on September 30, 2010 to remove unapproved colchicine products from the American drug-marketplace. Unapproved drugs have never experienced FDA’s testing procedure to greatly help ensure their security and efficacy. They could pose a substantial threat to the fitness of sufferers as they do not include basic safety information regarding correct dosage and routine, or warnings meant to help individuals avoid dangerous drug to drug interactions. The FDA made the removal of unapproved drugs a priority in 2006 when it announced the ‘Unapproved Drugs Initiative,’ which calls for removing unproven drugs from industry.